These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 29406823)
1. Biomarkers: Their Role in CFTR Modulator Therapies from Early Development to the Clinic. Bell SC; Wood ME Am J Respir Crit Care Med; 2018 Jun; 197(11):1375-1376. PubMed ID: 29406823 [No Abstract] [Full Text] [Related]
3. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator. Ong T; Ramsey BW Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186 [TBL] [Abstract][Full Text] [Related]
4. Effects of Lumacaftor/Ivacaftor in a Pediatric Cohort Homozygous for F508del-CFTR. Egan ME Am J Respir Crit Care Med; 2017 Apr; 195(7):849-850. PubMed ID: 28362199 [No Abstract] [Full Text] [Related]
5. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. Rehman A; Baloch NU; Janahi IA N Engl J Med; 2015 Oct; 373(18):1783. PubMed ID: 26510035 [No Abstract] [Full Text] [Related]
6. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. Wainwright CE; Elborn JS; Ramsey BW N Engl J Med; 2015 Oct; 373(18):1783-4. PubMed ID: 26510034 [No Abstract] [Full Text] [Related]
7. Orkambi in patients with severe disease - Bumps in the road to CFTR modulation. Horsley A; Barry P J Cyst Fibros; 2017 May; 16(3):311-312. PubMed ID: 28433526 [No Abstract] [Full Text] [Related]
8. A combination therapy for cystic fibrosis. Brodsky JL; Frizzell RA Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363 [TBL] [Abstract][Full Text] [Related]
9. The study of CFTR modulators in the very young. Flume PA Lancet Respir Med; 2019 Apr; 7(4):287-289. PubMed ID: 30686766 [No Abstract] [Full Text] [Related]
10. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant. Mitchell RM; Jones AM; Barry PJ Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080 [TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
12. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry. Elborn JS; Ramsey B; Wainwright C; Boyle M Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855 [No Abstract] [Full Text] [Related]
13. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis. Mayer-Hamblett N; Boyle M; VanDevanter D Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594 [TBL] [Abstract][Full Text] [Related]
14. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction. Brewington JJ; McPhail GL; Clancy JP Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802 [TBL] [Abstract][Full Text] [Related]
15. The PROSPECT Is Bright for CFTR Modulators. Montemayor K; Lechtzin N Ann Am Thorac Soc; 2021 Jan; 18(1):32-33. PubMed ID: 33385230 [No Abstract] [Full Text] [Related]
16. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Jones AM; Barry PJ Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414 [No Abstract] [Full Text] [Related]
17. The stony road to phe508del CFTR pharmacotherapy: smoothing the first rock. Tümmler B Lancet Respir Med; 2014 Jul; 2(7):508-9. PubMed ID: 24973279 [No Abstract] [Full Text] [Related]
18. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation. Bulloch MN; Hanna C; Giovane R Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346 [TBL] [Abstract][Full Text] [Related]